Fibrosis and ischemia: The real risks in hypertensive heart disease

被引:53
作者
Frohlich, ED [1 ]
机构
[1] Alton Ochsner Med Fdn & Ochsner Clin, New Orleans, LA 70121 USA
关键词
left ventricular hypertrophy; coronary flow reserve; hydroxyproline; angiotensin converting enzyme inhibition; angiotensin II; type II receptor antagonism; calcium antagonists;
D O I
10.1016/S0895-7061(01)02088-X
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The increased cardiovascular morbidity and mortality in hypertension are related to the target organs (ie, heart, brain, kidneys) involvement from vascular disease. Left ventricular hypertrophy (LVH), the major expression of cardiac involvement, is both a structural and functional adaptation to the afterload imposed by the vascular disease. Without this adaptation, cardiac failure would result much earlier in the natural history of hypertensive heart disease (HHD). However, LVH imposes an independent risk that is even greater than the risk associated with the height of systolic or diastolic pressure. The mechanisms that explain this risk have not been defined precisely, several have been postulated. Among these are the following: 1) coronary hemodynamic alterations associated with HHD (ie, increased coronary vascular and minimal vascular resistance, reduced coronary blood how and flow reserve, and increased blood viscosity); 2) enhanced predisposition for lethal cardiac arrhythmias, cardiac failure, and accelerated atherosclerosis of the coronary arteries (with exacerbation of the ischemia); and 3) collagen deposition and ventricular fibrosis. From the earliest controlled therapeutic trials, deaths from stroke and coronary heart disease were significantly reduced. However, more recent data have indicated that the prevalence of cardiac failure (CHF) continues to rise progressively. The nature of the CHF is no longer primarily from systolic dysfunction, but is now chiefly from diastolic dysfunction. Diastolic dysfunction occurs primarily in the elderly hypertensive patient or in the patient with ischemic heart disease, both of which are associated with increased collagen deposition. Indeed, these effects continue to be suggested by the data from the Framingham Heart Study as well as NHANES-III that indicate CHF is the most common diagnosis occurring in hospitalized patients over 65 years of age. In this report, both experimental and clinical evidence demonstrating that increased ventricular fibrosis occurs in the spontaneously hypertensive rats and in hypertensive patients are provided, and that treatment with the newer antihypertensive agents reduce ventricular hydroxyproline (ie. collagen) content while. at the same time, improve coronary hemodynamics. (C) 2001 American Journal of Hypertension, Ltd.
引用
收藏
页码:194S / 199S
页数:6
相关论文
共 64 条
[1]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[2]   DISPARATE STRUCTURAL EFFECTS ON LEFT-AND-RIGHT-VENTRICLES BY ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS AND CALCIUM-ANTAGONISTS IN ESSENTIAL-HYPERTENSION [J].
ARISTIZABAL, D ;
MESSERLI, FH ;
FROHLICH, ED .
AMERICAN JOURNAL OF CARDIOLOGY, 1994, 73 (07) :483-487
[3]   BIOCHEMICAL-COMPONENTS AND MYOCARDIAL PERFORMANCE AFTER REVERSAL OF LEFT-VENTRICULAR HYPERTROPHY IN SPONTANEOUSLY HYPERTENSIVE RATS [J].
ARITA, M ;
HORINAKA, S ;
FROHLICH, ED .
JOURNAL OF HYPERTENSION, 1993, 11 (09) :951-959
[4]  
ARITA M, 1993, J HYPERTENS, V11, pS354
[5]  
Bottcher M, 1999, CIRCULATION, V99, P1795
[6]   ANTIFIBROTIC EFFECTS OF SPIRONOLACTONE IN PREVENTING MYOCARDIAL FIBROSIS IN SYSTEMIC ARTERIAL-HYPERTENSION [J].
BRILLA, CG ;
MATSUBARA, LS ;
WEBER, KT .
AMERICAN JOURNAL OF CARDIOLOGY, 1993, 71 (03) :A12-A16
[7]   Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease [J].
Brilla, CG ;
Funck, RC ;
Rupp, H .
CIRCULATION, 2000, 102 (12) :1388-1393
[8]   ANGINA DUE TO CORONARY MICROVASCULAR DISEASE IN HYPERTENSIVE PATIENTS WITHOUT LEFT-VENTRICULAR HYPERTROPHY [J].
BRUSH, JE ;
CANNON, RO ;
SCHENKE, WH ;
BONOW, RO ;
LEON, MB ;
MARON, BJ ;
EPSTEIN, SE .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (20) :1302-1307
[9]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[10]   BLOOD-PRESSURE, STROKE, AND CORONARY HEART-DISEASE .2. SHORT-TERM REDUCTIONS IN BLOOD-PRESSURE - OVERVIEW OF RANDOMIZED DRUG TRIALS IN THEIR EPIDEMIOLOGIC CONTEXT [J].
COLLINS, R ;
PETO, R ;
MACMAHON, S ;
HEBERT, P ;
FIEBACH, NH ;
EBERLEIN, KA ;
GODWIN, J ;
QIZILBASH, N ;
TAYLOR, JO ;
HENNEKENS, CH .
LANCET, 1990, 335 (8693) :827-838